10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Avacta Group, a developer of Affimer biotherapeutics and research reagents, has agreed a strategic partnership with the cell line development company Selexis. 20 June 2019
US biotech major Amgen and the University of Washington's Institute for Protein Design (IPD) today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to the search for new medicines. 20 June 2019
Japanese conglomerate Fujifilm Corp has signed an agreement to invest 300 million yen ($2.8 million) into a biotech venture, PuREC Co, through underwriting its third-party allocation of shares. 20 June 2019
US biotech major Gilead Sciences has struck a deal with privately-held Nurix to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases. 19 June 2019
Onpattro (patisiran), the gene-silencing drug from US biotech Alnylam, has been approved for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy in Japan. 19 June 2019
Boston, USA-based cell therapy developer Gamida Cell and Switzerland’s Lonza today announced that they have entered into a strategic manufacturing agreement. 19 June 2019
Chinese cancer specialist BeiGene has entered into a second collaboration with SpringWorks Therapeutics, a spin-out from US pharma giant Pfizer. 18 June 2019
Much of the dialogue surrounding Roche’s oncology drugs is currently about the big-selling products at the end of their patent life, but the company has provided a timely reminder that its new innovations are a big deal too. 18 June 2019
Merck & Co has been granted a new label update for its immuno-oncology blockbuster, Keytruda (pembrolizumab), in metastatic small cell lung cancer (SCLC). 18 June 2019
Having already backed out of an option on a Parkinson’s disease program in 2017, Sanofi Genzyme is now pulling further out of its collaboration with USA-based Voyager Therapeutics, as the companies yesterday announced a restructuring of their gene therapy relationship. 18 June 2019
Tumor drug resistance specialist Deciphera Pharmaceuticals has inked a deal with Shanghai-based Zai Lab to advance the development and commercialization of ripretinib in China. 18 June 2019
Belgian immunotherapies developer Imcyse today announces that it has raised 35 million euros ($39.5 million) in a Series B financing round and through other channels. Imcyse is a spin-off from Belgium’s Katholieke Universiteit Leuven (KUL). 18 June 2019
At first glance, an observer might have predicted that shares in VBI Vaccines would have shot up based on the results of its PROTECT Phase III study, rather than to decline by more than 60% as they did on Monday morning. 17 June 2019
AstraZeneca could be on course to gain another indication with Calquence (acalabrutinib), a Bruton tyrosine kinase (BTK) inhibitor that already has accelerated US approval for mantle cell lymphoma (MCL). 17 June 2019
CASI Pharmaceuticals has revealed it has signed a license agreement for exclusive worldwide license and commercialization rights to an autologous anti-CD19 T-cell therapy product (CNCT19) from Juventas Cell Therapy, a China-based domestic company located in Tianjin City, China. 17 June 2019
The global cell therapy market size is expected to reach a value of $7.92 billion by 2025, rising at a compound annual growth rate (CAGR) of 5.34% during the forecast period. 17 June 2019
The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year. Now, before attention turns to the next major event, we recap some of the key highlights and learnings from the industry’s preeminent cancer conference. 17 June 2019
US pharma giant Pfizer today announced that it will acquire Array BioPharma, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. 17 June 2019